Dinitrochlorobenzene

PreclinicalSmall molecule

UUniversity of California, San Francisco

Dinitrochlorobenzene is one of 25 small molecule programs targeting AIDS. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AIDSCompleted

AIDSPreclinical

Completed

Competition

Competitive Landscape

25 competitors in AIDS

#DrugCompanyPhaseTrials

Tybost

Norvir

Thalomid

Aralen

Tivicay

Vemlidy

Emtriva

Andriol

Reyataz

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Implanon

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

HIV infection1 trial

Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.

Completed·TThe Honolulu Medical Group·Phase 1·NCT00002175·46 enrolled

AIDS1 trial

Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

Completed·UUniversity of California, San Francisco·N/A·NCT00002031

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Dinitrochlorobenzene. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dinitrochlorobenzene compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dinitrochlorobenzene. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of California, San Francisco

Dinitrochlorobenzene

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

HIV infection1 trial

AIDS1 trial

References

Drug Info

Quick Facts

Related News